Neoadjuvant Daromun Extends Recurrence-Free Survival Before Surgery in Stage III Melanoma
Daromun, the intralesional fusion protein combination of L19IL2 and L19TNF, continues to separate itself from the control strategy in resectable locally advanced melanoma. In the phase III PIVOTAL trial, the neoadjuvant approach preserved its advantage at longer follow-up, reinforcing a treatment sequence that uses local immune activation before surgery rather than waiting until after resection to intensify therapy. The updated analysis, drawn from a median follow-up of 36.8 months from random assignment, confirms statistically and clinically meaningful gains in recurrence-free survival and distant metastasis-free survival.
The trial enrolled 256 patients in the European Union with fully resectable stage III melanoma. A direct comparison was made between daromun followed by surgery and up-front surgery. The primary efficacy signal had already emerged earlier, with a hazard ratio of 0.59 for recurrence-free survival and a P value of .005 at a median follow-up of 21 months. With additional time on study, that benefit did not erode. Instead, the longer observation window strengthened confidence that the neoadjuvant effect was not a short-lived statistical fluctuation but a durable separation between the two treatment strategies.
This is a meaningful result in a disease where microscopic residual spread can be clinically silent for months before surfacing as local relapse or distant disease. Intralesional therapy offers a biological rationale that differs from standard adjuvant escalation: the intact tumor remains in place long enough for immune-directed treatment to interact with tumor antigens in situ, potentially priming a broader antitumor response before the lesion is removed. In melanoma, where immune responsiveness is often central to outcome, that sequence may matter as much as the drug exposure itself.
The study population was not uniform. PIVOTAL included 34 patients, or 13%, with de novo metastatic disease and 222 patients, or 87%, who had recurrent disease after prior surgery, with or without radiotherapy and or adjuvant systemic therapy. This mix gives the trial practical relevance for melanoma centers that routinely face both newly presenting advanced lesions and relapses after prior local management. The updated analysis addressed both the overall cohort and these clinically distinct subgroups, which is important because prior treatment exposure can alter both tumor biology and the immune microenvironment.
Consistency Across Overall and Recurrent Disease Subgroups
The updated dataset did more than extend follow-up. It also included new sensitivity analyses of event-free survival, performed in the overall population and in recurrent patient subgroups, with and without prior systemic therapies. Those post hoc analyses showed consistency with the primary endpoint and added robustness to the efficacy signal. In practical terms, the benefit did not appear to depend on one narrow patient subset or on an isolated analytic cut of the data.
For melanoma clinicians, subgroup consistency is rarely a cosmetic detail. A neoadjuvant regimen must demonstrate that its activity survives the realities of referral patterns, prior surgery, radiotherapy, and systemic treatment exposure. The PIVOTAL update suggests that daromun’s advantage persists even in a population shaped by prior intervention. Such a finding supports the idea that local immune stimulation can still be effective in recurrent disease, where the tumor has already proved capable of escaping earlier treatment pressure.
The report also confirms improvement in distant metastasis-free survival. That endpoint carries particular weight in melanoma because distant spread is what most often transforms a surgically manageable disease into a prolonged systemic challenge. Preventing or delaying metastatic dissemination before surgery implies that early immune engagement may be altering the course of occult disease, not simply reducing local tumor burden.
Safety Remained Stable With Longer Observation
No new safety signals of concern emerged in the updated analysis. For a neoadjuvant strategy, that matters because toxicity must remain compatible with timely surgery and acceptable perioperative recovery. Intralesional therapy is often judged not only by whether it works, but by whether it can be delivered without adding complexity that compromises operative planning. The longer follow-up did not reveal a late safety surprise that would weaken the appeal of the regimen.
In melanoma practice, safety and timing are tightly linked. A treatment that improves recurrence metrics but disrupts surgical readiness can lose its value at the bedside. Here, the absence of new concerns supports continued consideration of intralesional neoadjuvant therapy as a sequence that can be integrated before definitive resection without an obvious accumulating toxicity burden over time.
The trial’s design also lends weight to the result. Randomized phase III data in a fully resectable stage III population provide a stronger foundation than the smaller exploratory studies that often generate early excitement in melanoma immunotherapy. The PIVOTAL update does not claim a dramatic reinvention of the disease course, but it does show a reproducible advantage in clinically relevant endpoints that matter to surgeons, medical oncologists, and patients facing a high risk of recurrence after apparently complete resection.
Why Local Immune Activation Before Surgery May Matter
Daromun combines two immune-active components delivered intralesionally. L19IL2 is designed to amplify immune effector activity, while L19TNF contributes a tumor-directed inflammatory effect. In a resectable lesion, that combination may create a concentrated antitumor environment before surgery removes the source of antigen. The logic is straightforward: expose the immune system to tumor antigens while the target remains present, then remove the primary lesion after immune priming has begun.
That sequence may help explain why the benefit extends beyond simple local control. Melanoma is an immunogenic malignancy, and the boundary between local tumor destruction and systemic immune response is often porous. If the neoadjuvant injection triggers broader surveillance, the clinical payoff would be expected to appear first in recurrence-free survival and then in delayed distant spread, exactly the type of pattern reflected in the updated PIVOTAL results.
The current analysis still leaves some practical questions unanswered. The trial confirms benefit across longer follow-up, but the optimal place of daromun relative to other modern melanoma strategies remains unresolved from these data alone. The abstract does not provide a head-to-head comparison with checkpoint-based approaches, nor does it identify which biomarker features, if any, predict the greatest benefit. Those issues will shape how readily the regimen moves from a positive trial into routine sequencing decisions.
Even with those limits, the central message is stable. In fully resectable stage III melanoma, neoadjuvant daromun improved recurrence-free outcomes, maintained a favorable distant metastasis-free survival signal, and did so without new safety concerns at nearly three years of median follow-up. For a disease where relapse after surgery remains a defining threat, that combination of efficacy and tolerability is clinically consequential.